| Titre : | Employing patient-reported outcome (PRO) measures to support newly diagnosed patients with melanoma : Feasibility and acceptability of a holistic needs assessment intervention (2017) |
| Auteurs : | Grigorios Kotronoulas ; John Connaghan ; Jean Grenfell ; et al. |
| Type de document : | Article |
| Dans : | European Journal of Oncology Nursing (Vol. 31, December 2017) |
| Article en page(s) : | p. 59-68 |
| Langues: | Anglais |
| Descripteurs : |
HE Vinci Accompagnement du patient ; Diagnostic ; Mélanome ; Santé holistique |
| Mots-clés: | Mesures basées sur les résultats déclarés par le patient ; Faisabilité ; Acceptation |
| Résumé : |
Purpose
Living with a melanoma diagnosis can be challenging. We aimed to assess the feasibility, acceptability, and perceived value of a nurse-led intervention that utilised patient-reported outcome (PRO) measures to identify and address the supportive care needs of newly diagnosed patients with Stage I/II melanoma over the first 4 months post-diagnosis. Methods We conducted an exploratory, repeated-measures, single-arm, feasibility trial. One baseline (4 weeks post-diagnosis; T1) and one follow-up intervention session (4 weeks after wide local excision; T3) took place, two months apart. Patient survey data were collected monthly, at four assessment points (T1-T4), followed by exit interviews. Results A recruitment rate of 55% (10/18) was achieved. The skin cancer nurse specialist (CNS) performed 19 in-clinic patient assessments within 6 months. One patient missed their follow-up intervention session (90% retention rate). Three participants (30%) were lost to follow-up at T4. Patients endorsed the standardised use of easy-to-use PRO measures as a means to help them shortlist, report and prioritise their needs. The CNS viewed the intervention as a highly structured activity that allowed tailoring support priority needs. A sizeable reduction in information needs was found from T1 to T4 (Standardised Response Mean [SRM] change = −0.99; p Conclusions The intervention appears to be feasible in clinical practice and acceptable to both patients with newly diagnosed melanoma and clinicians. Future research is warranted to test its effectiveness against standard care. |
| Disponible en ligne : | Non |
Exemplaires (1)
| Cote | Support | Localisation | Section | Disponibilité |
|---|---|---|---|---|
| REV | Périodique papier | Woluwe | Espace revues | Consultation sur place uniquement Exclu du prêt |
